Gsk Respiratory Drugs

GSK, urinary tract infection (UTI and FDA

FDA greenlights GSK’s drug for UTIs in women and girls

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.

Reuters on MSN · 1d

US FDA approves GSK's urinary tract infection drug

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.

BioSpace · 14h

GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in the second half of this year.

Fierce Pharma1d

GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

pharmaphorum2d

GSK bolsters respiratory pipeline with Bellus Health buy

The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...

US FDA approves GSK's 'Blujepa' for treating UTIs in women and girls

The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...

BioSpace1d

GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

FierceBiotech24d

GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump

GSK's long-acting asthma drug halved attacks in phase 3 ... M.D., Ph.D., GSK’s global head of respiratory and immunology R&D, said in the release. “With nearly 40% of patients needing repeat ...

Yahoo Finance19d

Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?

GSK reported core earnings of 59 cents per ... and Other sales were up 9% in the fourth quarter. Sales of the respiratory drug Nucala were up 7% at CER, driven by strong patient demand in Europe ...

Nasdaq1mon

GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook

GSK plc GSK reported fourth-quarter 2024 core ... Sales of Apretude and Cabenuva rose 65% and 43%, respectively. Sales of the respiratory drug Nucala were up 7% during the quarter, driven by ...

Zacks.com on MSN2d

EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD

The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results